Bio-Rad: Free Products, Missing Records, and a Changed Verdict

The Bio-Rad FCPA whistleblower retaliation case produced a $10.92 million trial judgment after its general counsel reported suspected bribery involving extra products in China shipments and mismatched sales records. The Ninth Circuit changed that result in 2019, preserving the California verdict while setting aside the federal verdicts. Behind the headline was a problem an insider could recognize long before a courtroom became involved: the contracts, shipments and sales records were telling different stories.

Bio-Rad sells life science and clinical diagnostic products, including testing kits and systems used by laboratories and hospitals. Its general counsel’s internal report of suspected Foreign Corrupt Practices Act violations brought together missing customer-price records, unauthorized distributor agreements and concerns about free products. The court’s February 26, 2019 opinion explains both the commercial evidence and why the original employment judgment changed.

The Missing End-User Prices

The missing end-user prices came to light through a sales-documentation audit requested by Bio-Rad’s licensor, Life Technologies. According to the court’s account, the audit found around $30 million in royalty obligations because Bio-Rad lacked documentation of end-user prices, primarily in China. Missing paperwork already had a substantial business consequence before the general counsel took his concerns to the audit committee.

An earlier investigation had already raised concerns about Bio-Rad’s overseas sales. The court recounts that an internal audit flagged potential violations in Vietnam and Thailand in 2009, followed by an outside investigation that reported evidence of violations in those countries and Russia in September 2011. The investigators also flagged unusually high, unexplained commissions in China.

The general counsel and an in-house patent specialist repeatedly sought the missing sales documents. In November 2012, the patent specialist obtained a complete set for a single transaction and sent it to the general counsel. At trial, the general counsel testified that his colleague thought the documents showed bribery, and that the chief executive declined to act when told about the potential problem.

The requests also exposed how little checking had occurred at a major distributor. A senior manager in China told the general counsel that he had never visited the distributor to look for documents, despite its failure to supply them. For a business trying to reconcile the price paid by an end customer with its own sales records, that unanswered request mattered as much as the transaction packet that finally arrived.

Extra Products Behind the Cover Sheet

The reported product-padding scheme put one quantity on the paperwork and another in the shipment. The court described how the information moved from an employee in China through the patent specialist to the general counsel:

The general counsel later obtained around 160 sets of Chinese sales documents. The opinion says 30% showed the product-padding pattern described by the employee. That turned the concern from an account of one transaction into a recurring mismatch between documents and goods.

For someone in distribution, the quantities are part of the money trail. Free inventory changes what a distributor receives for the price it pays, and the general counsel’s memorandum identified the arrangement as a possible means of bribery. His concern also reached the books and records: the opinion describes shipping documents that did not match the billing documents of distributors or end users.

The Translation That Dropped the Compliance Terms

The Chinese distributor contracts differed from the approved English agreements in more than language. In January 2013, the general counsel discovered unauthorized contracts translated from an older template that lacked Foreign Corrupt Practices Act compliance provisions. The approved agreement and the agreement used locally were different documents.

Junior members of the legal team also reported unauthorized free-product incentives ranging from 1% to 3% of sales when salespeople reached specified targets. They described an approximately $1 million financial impact. These were concerns about who authorized the commercial terms and what those terms delivered, alongside the suspected bribery.

That is why the actual translation belongs beside the approved agreement. A reviewer looking only at the English template could see compliance terms that never reached the local contract. We see a safeguard that disappeared in translation, precisely where it was supposed to work.

What Reached the Audit Committee

The February 8, 2013 audit-committee memorandum connected the free-product concerns, missing audit documents and distributor contracts without the law’s compliance language. The general counsel reported his belief that the China business had serious bribery and accounting problems and that senior management likely knew about them. The memorandum gave the committee a commercial account of why those concerns belonged together.

He recommended an in-depth investigation and disclosure of his suspicions to government agencies and the company’s auditors. He also pointed to forthcoming meetings with the government about management’s approach to compliance. His concern was that discussions about leadership would leave out potentially serious problems already raised inside the company.

The committee authorized an outside investigation. According to the court’s account, after the chief executive learned about the memorandum, he discussed possible administrative leave with the head of human resources. The outside investigation later reported finding no evidence to date of a Foreign Corrupt Practices Act violation in China, and the chief executive fired the general counsel three days after that report to the board.

Bio-Rad argued at trial that the dismissal reflected poor performance and a dysfunctional relationship with management. It also argued that the memorandum arose from concern about job security. The jury found for the general counsel on all three claims, making the company’s response to the report part of the case alongside the underlying sales documents.

Why the Verdict Changed

The Ninth Circuit preserved the California verdict against Bio-Rad and the damages attached to it, including $5 million in punitive damages. It set aside the Sarbanes-Oxley verdict and the Dodd-Frank verdict. The latter change removed approximately $2.96 million from the trial judgment, the additional lost-pay damages awarded under Dodd-Frank.

The Sarbanes-Oxley problem concerned what the jury had been told. The jury instructions treated the Foreign Corrupt Practices Act itself as a rule of the Securities and Exchange Commission, and the court said that was wrong. A separate rule against falsifying books and records still mattered: the court concluded that the shipping and billing discrepancies could support the general counsel’s belief that records had been falsified and needed further investigation.

The audit committee’s chair had testified that he thought the general counsel did a terrific job by raising his concerns. The court pointed to that response and the further investigation the memorandum prompted when explaining why the accounting evidence could still support a verdict for him. The report had given the board something concrete to investigate.

The Separate Bio-Rad FCPA Settlement

Bio-Rad separately agreed to pay $40.7 million to the Securities and Exchange Commission to resolve charges concerning Russia, Vietnam and Thailand. The agency’s November 3, 2014 announcement alleged that approximately $7.5 million in bribes had enabled Bio-Rad to earn $35 million in illicit profits. This corporate enforcement concerned different countries and transactions from the reported China concerns in the employment case.

The SEC’s settled order alleged that Bio-Rad’s Singapore subsidiary supplied Vietnamese distributors at deep discounts, with the products then resold to government customers at full price. Part of the difference allegedly funded payments to officials. The agency alleged that cash reached officials at government-owned hospitals and laboratories in exchange for purchases of Bio-Rad products.

The Russian allegations supplied another example of paperwork concealing the commercial reality. The Securities and Exchange Commission alleged that agents collected large commissions despite lacking employees and the capacity to perform the promised services. It also alleged that legal and finance staff did not receive translated agreements, yet finance continued approving commission payments.

According to the Securities and Exchange Commission’s order, a country manager estimated distribution costs at 2% to 2.5% in one instance, while the agents’ commissions ran from 15% to 30%. The agency also alleged that Bio-Rad used a separate distributor on several of the same government contracts and that many products required little installation or training. Those were the kinds of services the agents’ agreements purported to buy.

The order further alleged that a controller instructed an employee to use codes when discussing the agents’ invoices. It also alleged that managers signed assurances that internal controls were adequate while the payments continued. On the agency’s account, we see managers certifying safeguards while withholding the documents needed to test them.

Those allegations explain why a person who knows the distributor, the actual services or the local contract can bring something an expense label misses. They also keep the money in its proper place: the agency’s resolution addressed the company’s conduct, while the general counsel’s judgment addressed his employment. A whistleblower reward is a separate question from either amount. For foreign bribery and company accounting violations, the SEC Whistleblower Program can pay eligible whistleblowers 10% to 30% of qualifying sanctions collected. The False Claims Act concerns a separate false claim against U.S. government money. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

What the Medical-Distribution Business Reveals

A distributor’s margin can finance a payment that never appears as a bribe in the manufacturer’s ledger. In 2015 remarks on pharmaceutical-industry controls, the Securities and Exchange Commission’s enforcement director described that mechanism and emphasized third-party review, expense controls, escalation of warning signs and internal audits. Bio-Rad’s alleged Vietnam discount arrangement gives that industry concern a concrete commercial form.

The 2022 Journal of Forensic and Investigative Accounting paper Fresenius Medical Care: A Case Study on the FCPA examines a related health care pattern. Its account of the SEC’s China findings describes bonuses to publicly employed doctors, recorded as marketing fees, and an internal audit that identified payments to an agent without supporting service reports. The useful parallel is the missing connection between a payment description and the work actually performed.

The Documents an Insider Can Connect

The strongest evidence in this case connected records that different parts of the business held. An end-user price belonged beside the sale, a shipment quantity beside the billing documents, and the local distributor agreement beside the approved English version. The audit-committee memorandum then connected those discrepancies to what management had been told.

That is the value of knowing how the business actually runs. A sales, finance, distribution or compliance employee may understand why a contract term changed, why a shipment contained extra products or why a requested record never arrived. We work with that knowledge to understand the transaction, the decision and the people who could explain it.

Your Knowledge of the Deal Matters

If you know why the local agreement differs from the approved contract, or what the shipment and sales records leave out, speak with our whistleblower experts. We build the case around your understanding of the business, bring in FCPA whistleblower lawyers who know cross-border sales and accounting evidence, and stay beside you through the process. Concerns about privilege or retaliation belong in that conversation, with a team focused on you and the case your information can support.